Spots Global Cancer Trial Database for Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity

Official Title: Phase 0 Study for the Development of Immunological Assays for the Evaluation of WT-1, Survivin and HPV16 E7 Tumor Antigens Specific Immune Responses in Cancer Patients

Study ID: NCT02016833

Conditions

Ovarian Serous Adenocarcinoma

Undifferentiated Carcinoma of Ovary

Cervical Cancer

Cervical Intraepithelial Neoplasia, Grade 3

Acute Myeloid Leukemia

Chronic Myeloid Leukemia

Interventions

Blood Sampling

Study Description

Brief Summary: This study is a clinical study aiming at establishing immunological assays for the qualitative and quantitative evaluation of WT-1, Survivin and HPV16 E7-specific immune responses in cancer patients. Such a study will allow the development of suitable immunological tools to be used in assessing response in a subsequent phase I study aiming at evaluating therapeutic vaccine candidates targeting WT-1, Survivin and/or HPV16 E7-expressing tumors. In addition, this study will help defining the baseline cancer-associated immune responses in the selected patient population. Cervical and ovarian cancer patients, as well as leukemia patients, will be included in this study. WT-1, Survivin and HPV-specific immune responses will be monitored in these patients by ex vivo and cultured IFNg ELISpot as well as tetramer staining.

Detailed Description: